Drug comparison

Semaglutide vs Tirzepatide

JV
John Venzor, DO · Board-certified Internal Medicine
Medically reviewed · Last updated July 6, 2026

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the two leading weekly injections for weight loss and type 2 diabetes. Tirzepatide acts on two gut-hormone receptors instead of one, and produced greater average weight loss in clinical trials.

SemaglutideOzempic, Wegovy, Rybelsus
TirzepatideMounjaro, Zepbound
Drug class

GLP-1 receptor agonist

GIP / GLP-1 receptor agonist

What it is

A once-weekly injectable (also an oral tablet) that curbs appetite and lowers blood sugar, widely used for weight loss and type 2 diabetes.

A once-weekly injectable that activates two gut hormone receptors (GIP and GLP-1), often producing greater average weight loss than semaglutide in trials.

Category

Weight loss / type 2 diabetes

Weight loss / type 2 diabetes

FDA-approved uses
  • Chronic weight management (as Wegovy)
  • Type 2 diabetes (as Ozempic and Rybelsus)
  • Reducing cardiovascular risk in adults with type 2 diabetes and known heart disease
  • Chronic weight management (as Zepbound)
  • Type 2 diabetes (as Mounjaro)
  • Moderate-to-severe obstructive sleep apnea in adults with obesity (as Zepbound)
Typical dosing
  • Weight management (Wegovy): titrate over ~16–20 weeks to 2.4 mg subcutaneously once weekly
  • Type 2 diabetes (Ozempic): 0.25 mg weekly to start, titrated to 0.5–2 mg once weekly
  • Oral (Rybelsus): 3 mg daily to start, then 7–14 mg once daily on an empty stomach
  • Doses are increased slowly to limit nausea
  • Start 2.5 mg subcutaneously once weekly for 4 weeks, then increase in 2.5 mg steps as tolerated
  • Maintenance range 5–15 mg once weekly
  • Doses are increased slowly to limit nausea
Common & serious side effects
Common
  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Abdominal pain
  • Reduced appetite
Serious
  • Pancreatitis
  • Gallbladder disease
  • Kidney injury from dehydration
  • Diabetic retinopathy complications
  • Severe low blood sugar when combined with insulin or a sulfonylurea
Common
  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Abdominal pain
  • Reduced appetite
  • Injection-site reactions
Serious
  • Pancreatitis
  • Gallbladder disease
  • Kidney injury from dehydration
  • Severe low blood sugar when combined with insulin or a sulfonylurea
  • Hypersensitivity reactions
Who it's for
  • Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition
  • Adults with type 2 diabetes
  • Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition
  • Adults with type 2 diabetes
Contraindications
  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Known serious hypersensitivity to semaglutide
  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Known serious hypersensitivity to tirzepatide
Warnings
  • Risk of pancreatitis — stop if suspected
  • Not for use in type 1 diabetes or diabetic ketoacidosis
  • May delay gastric emptying and affect absorption of oral medications
  • Use in pregnancy is not recommended; stop at least 2 months before a planned pregnancy
  • Risk of pancreatitis — stop if suspected
  • May reduce the effectiveness of oral contraceptives; a backup or non-oral method is advised after starting and after each dose increase
  • May delay gastric emptying and affect absorption of oral medications
  • Not for use in type 1 diabetes or diabetic ketoacidosis
Boxed warning
In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether it causes such tumors, including medullary thyroid carcinoma (MTC), in humans. It is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
In rodents, tirzepatide causes thyroid C-cell tumors. It is unknown whether it causes such tumors, including medullary thyroid carcinoma (MTC), in humans. It is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Bottom line: which should I choose?

Choose tirzepatide if maximum weight loss is the priority and you tolerate the gradual dose increases, since trial data favor it for total pounds lost. Choose semaglutide if you want the longer real-world track record, an oral option (Rybelsus), or its specific cardiovascular-risk indication. Both are once weekly, both cause nausea that eases with slow titration, and both carry the thyroid C-cell tumor boxed warning. A clinician confirms which is appropriate and available to you.

See if GLP-1 weight-loss treatment is right for you U.S.-licensed clinicians review your intake and prescribe when appropriate.
Get started

Common questions

On average, tirzepatide produced greater weight loss in trials, though individual results vary and both are highly effective.
Both mainly cause gastrointestinal side effects like nausea. Tirzepatide can also temporarily reduce the effectiveness of oral birth control.
Yes, many people switch under a clinician's guidance, usually restarting titration to limit nausea.
References
  1. U.S. FDA. Prescribing Information — Wegovy (semaglutide)
  2. U.S. FDA. Prescribing Information — Ozempic (semaglutide)
  3. U.S. FDA. Prescribing Information — Zepbound (tirzepatide)
  4. U.S. FDA. Prescribing Information — Mounjaro (tirzepatide)

Care for real conditions, prescribed online

U.S.-licensed clinicians review your intake and prescribe when appropriate — no waiting room.

See if GLP-1 weight-loss treatment is right for you
U.S.-licensed clinicians Transparent pricing No insurance needed